Motor dysfunction as a primary symptom predicts poor outcome: multicenter study of glioma symptoms.

brain neoplasm cognitive disorder epilepsy glioma headache motor dysfunction prognosis symptoms

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2023
Historique:
received: 02 10 2023
accepted: 27 11 2023
medline: 19 1 2024
pubmed: 19 1 2024
entrez: 19 1 2024
Statut: epublish

Résumé

The objectives of this study were to investigate the prognostic value of primary symptoms and leading symptoms in adult patients with diffuse infiltrating glioma and to provide a clinical perspective for evaluating survival. This study included a retrospective cohort from two tertiary university hospitals ( The most common primary symptoms were epileptic seizure (30.8% retrospective, 28.2% prospective), cognitive disorder (13.2% retrospective, 16.0% prospective), headache (8.6% retrospective, 12.8% prospective), and motor paresis (7.0% retrospective, 7.1% prospective). Symptoms that predicted better survival were epileptic seizure and visual or other sense-affecting symptom in the retrospective cohort and epileptic seizure and headache in the prospective cohort. Predictors of poor survival were cognitive disorder, motor dysfunction, sensory symptom, tumor hemorrhage, speech disorder and dizziness in the retrospective cohort and cognitive disorder, motor dysfunction, sensory symptom, and dizziness in the prospective cohort. Motor dysfunction served as an independent predictor of survival in a multivariate model (OR = 1.636). Primary and leading symptoms in diffuse gliomas are associated with prognoses in retrospective and prospective settings. Motor paresis was an independent prognostic factor for poor survival in multivariate analysis for grade 2-4 diffuse gliomas, especially in glioblastomas.

Sections du résumé

Background and objectives UNASSIGNED
The objectives of this study were to investigate the prognostic value of primary symptoms and leading symptoms in adult patients with diffuse infiltrating glioma and to provide a clinical perspective for evaluating survival.
Methods UNASSIGNED
This study included a retrospective cohort from two tertiary university hospitals (
Results UNASSIGNED
The most common primary symptoms were epileptic seizure (30.8% retrospective, 28.2% prospective), cognitive disorder (13.2% retrospective, 16.0% prospective), headache (8.6% retrospective, 12.8% prospective), and motor paresis (7.0% retrospective, 7.1% prospective). Symptoms that predicted better survival were epileptic seizure and visual or other sense-affecting symptom in the retrospective cohort and epileptic seizure and headache in the prospective cohort. Predictors of poor survival were cognitive disorder, motor dysfunction, sensory symptom, tumor hemorrhage, speech disorder and dizziness in the retrospective cohort and cognitive disorder, motor dysfunction, sensory symptom, and dizziness in the prospective cohort. Motor dysfunction served as an independent predictor of survival in a multivariate model (OR = 1.636).
Conclusion UNASSIGNED
Primary and leading symptoms in diffuse gliomas are associated with prognoses in retrospective and prospective settings. Motor paresis was an independent prognostic factor for poor survival in multivariate analysis for grade 2-4 diffuse gliomas, especially in glioblastomas.

Identifiants

pubmed: 38239655
doi: 10.3389/fonc.2023.1305725
pmc: PMC10794640
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1305725

Informations de copyright

Copyright © 2024 Kivioja, Posti, Sipilä, Rauhala, Frantzén, Gardberg, Rahi, Rautajoki, Nykter, Vuorinen, Nordfors, Haapasalo and Haapasalo.

Déclaration de conflit d'intérêts

Authors HH and JH were employed by the company Fimlab Laboratories Ltd, which is a public limited company. Individual funding outside of this submitted work: Academy of Finland #17379 to JP; Government’s Special Financial Transfer tied to academic research in Health Sciences, Finland #11129 to JP; the Maire Taponen Foundation. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Tomi Kivioja (T)

Faculty of Medicine and Health Technology, University of Tampere, Tampere, Finland.

Jussi P Posti (JP)

Neurocenter, Department of Neurosurgery and Turku Brain Injury Center, Turku University Hospital and University of Turku, Turku, Finland.

Jussi Sipilä (J)

Department of Neurology, Siun Sote, North Karelia Central Hospital, Joensuu, Finland.
Clinical Neurosciences, University of Turku, Turku, Finland.

Minna Rauhala (M)

Faculty of Medicine and Health Technology, University of Tampere, Tampere, Finland.
Department of Neurosurgery, Tampere University Hospital and Tampere University, Tampere, Finland.

Janek Frantzén (J)

Department of Neurosurgery, Turku University Hospital and University of Turku, Turku, Finland.

Maria Gardberg (M)

Turku University Hospital, Tyks Laboratories, Pathology and Institute of Biomedicine, University of Turku, Turku, Finland.

Melissa Rahi (M)

Department of Neurosurgery, Turku University Hospital and University of Turku, Turku, Finland.

Kirsi Rautajoki (K)

Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland.

Matti Nykter (M)

Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland.

Ville Vuorinen (V)

Department of Neurosurgery, Turku University Hospital and University of Turku, Turku, Finland.

Kristiina Nordfors (K)

Department of Pediatrics, Tampere University Hospital, Tampere, Finland.

Hannu Haapasalo (H)

Fimlab Laboratories Ltd., Tampere University Hospital, Tampere, Finland.

Joonas Haapasalo (J)

Department of Neurosurgery, Tampere University Hospital and Tampere University, Tampere, Finland.
Fimlab Laboratories Ltd., Tampere University Hospital, Tampere, Finland.

Classifications MeSH